Follows women with Fabry disease and their babies through pregnancy and breastfeeding
Observes pregnancy and breastfeeding in women with Fabry disease taking migalastat.
Plain-language title generated from the registry record
Registry title: A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Key facts
- Where
- Philadelphia, United StatesSee the site
Where in United States
- Amicus Therapeutics, Inc. Pregnancy RegistryPhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amicus Therapeutics
- Trial code
- NCT04252066
- Record updated
- 28 October 2026
- Original description
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.Read full original descriptionShow less
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.
Inclusion: Female patients meeting the following criteria will be eligible for study enrollment:; Patients with Fabry disease who are pregnant and/or breastfeeding, whether or not they are exposed to migalastat; Able and willing to provide informed consent or assent, if applicable; Able and willing to provide HCP contact information.
Exclusion: None.